ADDED
As of March 6, 2026, there were 105,854,108 and 104,871,987 shares of the Company s common stock, par value $ 0.0001 , issued and outstanding.
Form 10 K Summary 89 Signatures 90 In this Annual Report on Form 10-K, all references to Wellgistics Health, Inc., we, us, our or the Company mean Wellgistics Health, Inc.., and its wholly-owned subsidiaries, except where it is made clear that the term means only Wellgistics Health, Inc.
There can be no assurance that Wellgistics Health Common Stock will be approved for listing on Nasdaq or, if approved, will continue to be so listed, or that Wellgistics Health will be able to comply with the continued listing standards of Nasdaq.
If and when our Common Stock is publicly traded, it may be subject to the penny stock rules which may make it more difficult to sell our Common Stock.
Our common stock is subject to a Nasdaq minimum bid price deficiency notice, and failure to regain compliance could result in the delisting of our common stock from The Nasdaq Capital Market.
On December 10, 2025, we received a deficiency letter from the Nasdaq Listing Qualifications Staff notifying us that the closing bid price of our common stock had fallen below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) for the 30 consecutive business day period between October 27, 2025 and December 9, 2025.
We were granted an initial compliance period of 180 calendar days, or until June 8, 2026, to regain compliance with the Bid Price Rule.
To regain compliance, the closing bid price of our common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days prior to June 8, 2026.
If we do not regain compliance within the initial compliance period, we may be eligible for an additional 180-day compliance period, provided we meet all applicable continued listing requirements and notify Nasdaq of our intention to cure the deficiency, including through a reverse stock split if necessary.
If we are unable to regain compliance during any applicable compliance period, our common stock will be subject to delisting from The Nasdaq Capital Market, at which point we may appeal the delisting determination to a Nasdaq hearings panel.
REMOVED
As of March 20, 2025, there were 51,944,397 shares of the Company s common stock issued and outstanding.
Form 10 K Summary 83 Signatures 84 In this Annual Report on Form 10-K (this Annual Report ), all references to Wellgistics Health, Inc., Wellgistics Health, we, us, our or the Company mean Wellgistics Health, Inc., and its wholly-owned subsidiaries, except where it is made clear that the term means only Wellgistics Health, Inc.
There can be no assurance that Wellgistics Health common stock will be able to comply with the continued listing standards of the Capital Market tier of The Nasdaq Stock Market LLC ( Nasdaq ).
Our common stock is publicly traded and may be subject to the penny stock rules which may make it more difficult to sell our common stock.
Our directors and officers, including Brian Norton, Chief Executive Officer, and Vishnu Balu, Chief Financial Officer, have years of significant experience in the pharmaceutical industry and other sectors related to our business.
The ability to maintain business channels, service existing pharmacies from a wholesale product distribution perspective, and service Wellgistics Health s patient base at the pharmacy will all be potential areas for adverse impacts to Wellgistics Health s financial condition and operations due to everchanging regulations and requirements to maintain contracts and licenses.
Wellgistics Health s wholesale operations will retain state licenses for whole distribution from the various state boards of pharmacy or equivalent along with the federal level as maintained by the FDA, third-party logistics and controlled substance licenses from all state boards of pharmacy, and an accreditation with the NABP and Accredited Drug Distributor.
24 Wellgistics Health s pharmacy division has the equivalent of 32 state board of pharmacy licenses along with the District of Columbia.
Many of these licenses include the ability to dispense controlled substance with only a few states retaining waivers for exemption.
The pharmacy will also have a Florida state Medicaid contract, several National Provider Identifier numbers, and a Drug Enforcement Agency ( DEA ) certificate.